- Our LinkedIn Page
- Our Twitter Feed
- Our Facebook Page
- Newsletter Subscribe to our e-newsletter. Current Issue
- Our Flickr Feed
- Our YouTube Feed
Tags
patents drug development IPO BIO Investor Forum BIO business development 2011 BIO International Convention economy biotech industry patent Partnering biotechnology economic development FDA Food and Drug Administration China Biotechnology Industry biofuels BIO International Convention BIO Official Bloggers ProgamAuthors
- Abigail Hirsch
- Alan Eisenberg
- BIOtechNOW Editor
- Bruce Dale
- Celia Economides
- Colleen Lerro
- David Thomas, CFA
- George Goodno
- George MacDougall
- Jason Corum
- Jeff Joseph
- Jim Greenwood
- Karen Batra
- Kelly Cappio
- Lila Feisee
- Matt Carr
- Nathan Schock
- Paul Winters
- Paulina Ibarra
- Robbi Lycett
- Roy Zwahlen
- Sarah Sneeringer
- Sondra Behan
- Stephanie Fischer
- Stephen Marmaras
- Tracy Cooley
Business of Biotech
Archive
- January 2012 (3)
- December 2011 (2)
- October 2011 (3)
- August 2011 (3)
- July 2011 (2)
- June 2011 (12)
- April 2011 (2)
- January 2010 (1)
- November 2009 (1)
- October 2009 (47)
- September 2009 (37)
- August 2009 (1)
- June 2008 (3)
- May 2008 (2)
- April 2008 (1)
- February 2008 (6)
Category Archives: Business of Biotech
Reverse Mergers: A Company is Ready to Go Public, or it’s Not
The latest IPO window has stalled. There have been five IPO withdrawals since June and around 30 since 2005. Global macro events are threatening to completely shut it. Reverse mergers have become an increasingly popular option with eight transactions in the last year. Unfortunately, 47 percent of reverse mergers have decreased in value post-close since 2008. At the 2011 BIO Investor Forum, a panel of experts examined the current financing environment and what private executive Read More >
Boosting Investment in Biotech
The President’s Council on Jobs and Competitiveness issued an interim report with suggestions to increase job creation and growth in the U.S., as well as plans for encouraging investment in the industry. Of particular interest to the biotech industry, the report offers suggestions for streamlining the FDA approval process. The report also outlines ideas for eliminating capital gains on investments of $25 million or less that are held for at least five years and recommends Read More >
BayBio Announces Lifetime Achievement DiNA Award Recipient
Dr. Michael Hunkapiller has been named BayBio’s 2011 Lifetime Achievement DiNA Award recipient. He will be honored on Thursday, November 3rd, at the 2011 Pantheon Awards Ceremony, an annual program hosted by BayBio, a life science trade association representing the industry in Northern California. From the invention of the DNA sequencer during his days at Caltech, to the introduction of first automated DNA sequencer in 1986 and the realization of the Human Genome Mapping Project Read More >
How to Stand Out From the Crowd; Promoting Oklahoma Bioscience
BIO’s annual International Convention has emerged as a must-attend event for countries, states and regions that are hungry for industry investment. The convention gives them the ideal platform to publicize and promote what they have to offer to industry leaders in terms of economic development opportunities. International and domestic public officials take the time to attend because they recognize the enormous potential of the industry. This year’s event drew more than 100 public officials and Read More >
State Deficits to Shrink & Taxes Drop – Good News for Biotech
Forecasters at the National Conference of State Legislatures’ 2011 Legislative Summit expect a dramatic reduction of state deficits in the coming years, along with business-friendly tax-cuts. The projections are based on a survey of budget officials in all 50 states last month, said Corina Eckl, director of state services for NCSL. Eckl also noted an emerging trend in which state governors and legislatures are allowing for the expiration of temporary business taxes. Notably, the Michigan Business Read More >
